Ms Hewson is a former investment banker with over 35 years of experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has extensive financial markets, risk management and investment management expertise. She has long-term Non-Executive experience in a number of sectors bringing a breadth of experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture and the changing external environment. In 2009, Ms Hewson was made an Officer in the Order of Australia for her services to the broader community and to business. Currently, she is Director of Reserve Bank of Australia (since April 2021) Director of Infrastructure SA (since January 2019); Former Director of BHP Group Limited and BHP Group Plc (from March 2010 to November 2019),Stockland Group (from March 2009 to September 2018) Former Trustee Westpac Foundation (from May 2015 to May 2019) and Former Member of Federal Government Growth Centres Advisory Committee (from January 2015 to May 2021). She is Chair of the Corporate Governance Committee, member of the Risk Management Committee and Human Resources Committee.

Ms Watkins has experience of manufacturing, agriculture, consumer goods, retail and financial services. Ms Watkins was most recently the group managing director of ASX-listed Coca-Cola Amatil Limited, where she was responsible for operations in Australia, New Zealand, Indonesia and across the South Pacific region. Ms Watkins holds a Bachelor of Commerce from the University of Tasmania, is a fellow of the Institute of Chartered Accountants, the Financial Services Institute of Australasia, and the Australian Institute of Company Directors. Currently, she is Director of Reserve Bank of Australia (since Dec 2020); Director Wesfarmers Limited (effective from 1 September 2021); Chancellor, University of Tasmania (effective from 1 July 2021); Director of Centre for Independent Studies (since December 2011); Director of Business Council of Australia (since August 2015); and Former Group Managing Director of Coca-Cola Amatil Limited (from March 2014 to May 2021). She is Member of the Risk Management and Human Resources Committee.

Dr McNamee has experience in the biopharmaceutical industry, with a focus on strategy and creating long-term shareholder value. Dr McNamee was the Chief Executive Officer and Managing Director of CSL from 1990 until 2013. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. Currently, he is Chair of Geoff Ogilvy Foundation (since May 2021) and Chair of Genesis Care Limited (since July 2019). He is Member of the Innovation, Development Committee, Corporate Governance and Market Disclosure Committee.

Mr Cuthbertson has over 35 years of experience in medical research and biotech development with large biopharmaceutical companies and medical organizations. He also has Non-Executive director experience. Prior to CSL, he was a senior scientist at Genentech Inc, a biotechnology company dedicated to pursuing ground-breaking science to discover and develop medicine for people with life-threatening diseases. Professor Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne, Australia and the National Institutes of Health in Maryland, US. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. Currently, he is Director of the Centre of Eye Research Australia (since March 2017),Grattan Institute (since January 2019) and Member of the Council of the University of Melbourne (since January 2020). He is Chair of the Innovation and Development Committee.

Mr Brook has experience in diverse industries, including mining, finance, manufacturing and chemicals. In particular, Mr Brook has insight and experience in relation to risk, capital discipline, change management, corporate culture and creating shareholder value. Mr Brook was chief financial officer of WMC Resources Limited from 2002 to 2005. He also held key executive roles including deputy chief finance officer of ANZ Banking Group Limited, group chief accountant of Pacific Dunlop Limited and general manager, Group Accounting positions at CRA Limited and Pasminco Limited. Currently he is Director of Djerriwarrh Investments Limited, Guide Dogs Victoria,Incitec Pivot Limited, and Former Director of the Deep Exploration Technologies Co-operative Research Center Limited. He is Chair of risk committee and member of corporate governance committee.

Prof Maskell has international experience in science and commerce, developed across a 30-year career in research, academia and entrepreneurship. Prof Maskell is the Vice-Chancellor of the University of Melbourne. Prior to this he was Senior Pro-Vice-Chancellor at the University of Cambridge in the United Kingdom, where he was responsible for planning and resources for the institution's operations. As research specialist in infectious diseases, Professor Maskell has also held roles at the University of Oxford, Imperial College London and Wellcome Biotech. Prof Maskell has had experience across the private sector, involved in the commercialisation of research initiatives. He has co-founded several biotech companies, including Arrow Therapeutics, which was sold to biopharmaceutical company AstraZeneca, and Discuva, which was sold to Summit Therapeutics. He has also served as a Non-executive Director of Genus Plc, a FTSE 250 company.

Mr Perreault has more than 35 years of experience across both the global biotech and pharmaceutical industries. He was appointed Chief Executive Officer and Managing Director of CSL Limited in July 2013, and was appointed to the CSL Board of Directors the same year. Mr Perreault, who previously served as CSL Behring's president, joined CSL in 2004 with the acquisition of Aventis Behring. Prior to CSL, he spent more than 15 years in key senior roles at Wyeth-Ayerst Laboratories, now part of Pfizer. Currently, he is Director of the US Pharmaceutical Research and Manufacturers of America Association (PhRMA) (since December 2020). He is Member of the Innovation and Development Committee and Securities and Market Disclosure Committee.

Ms McDonald has executive and Non-Executive experience in a number of sectors including law, medical research, manufacturing and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance and change management. Ms McDonald is a former lawyer with over 30 years of experience in the legal sector. She was previously a partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She held the role of National Head of Mergers and Acquisitions and was Chair of the Corporations Committee of the Business Law Section of the Law Council of Australia and a member of the Australian Takeovers Panel for nine years. Currently, she is Director of Nanosonics Limited (since October 2016); Director of Nufarm Limited (since March 2017); Director of the Walter & Eliza Hall Institute of Medical Research (since October 2016). She is member of risk committee and human resources committee.

Dr Clark has executive and Non-Executive experience across a range of sectors, including scientific research, health, investment banking and financial services, education and mining. Through her roles, Dr Clark brings strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance. In 2014 Dr Clark was made a Companion of the Order of Australia for eminent service to scientific research and development. Dr Clark was chief executive of the Commonwealth Scientific and Industrial Research Organisation (CSIRO) from 2009 until November 2014. Prior to joining CSIRO, she was a director at NM Rothschild and Sons (Australia) and held senior positions at BHP, including vice president (Technology) and vice president (Health, Safety and Environment). Currently she is Director of Rio Tinto Limited and Rio Tinto Plc (since November 2014) Member of the Australian Advisory Board of the Bank of America, (since July 2010); Member of the Global Advisory Council of the Bank of America Corporation (since December 2019); Deputy Chancellor of Monash University (since January 2021); Chair of the Australian Space Agency Advisory Board (since January 2021); Former Director of Care Australia Limited (from May 2015 to June 2020); and Head of the Australian Space Agency (from June 2018 to December 2020). She is Chair of the Human Resources Committee; Member of the Corporate Governance and Innovation and Development Committee.

-

-

-

-

-

-

-

-

-

-